HUP0301479A2 - Cilansetron alkalmazása nemobstipációs férfi IBS-betegek kezelésére szolgáló gyógyszerkészítmény elżállítására - Google Patents

Cilansetron alkalmazása nemobstipációs férfi IBS-betegek kezelésére szolgáló gyógyszerkészítmény elżállítására

Info

Publication number
HUP0301479A2
HUP0301479A2 HU0301479A HUP0301479A HUP0301479A2 HU P0301479 A2 HUP0301479 A2 HU P0301479A2 HU 0301479 A HU0301479 A HU 0301479A HU P0301479 A HUP0301479 A HU P0301479A HU P0301479 A2 HUP0301479 A2 HU P0301479A2
Authority
HU
Hungary
Prior art keywords
cilansetron
obstipated
pharmaceutical compositions
ibs patients
treating non
Prior art date
Application number
HU0301479A
Other languages
English (en)
Inventor
Egbertus Hendrikus Evert Biesheuvel
Steven David Caras
Werner Cautreels
Heinz Günter Krause
Albertus Hermannus Dirk Plekkenpol
Claus Rudolf Steinborn
Original Assignee
Solvay Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10123447A external-priority patent/DE10123447A1/de
Application filed by Solvay Pharmaceuticals Gmbh filed Critical Solvay Pharmaceuticals Gmbh
Publication of HUP0301479A2 publication Critical patent/HUP0301479A2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány cilansetron nem-székrekedéses hímnemű IBS-betegekkezelésére szolgáló gyógyszerkészítmények előállítására vonatkozik. Ó
HU0301479A 2000-07-26 2001-07-18 Cilansetron alkalmazása nemobstipációs férfi IBS-betegek kezelésére szolgáló gyógyszerkészítmény elżállítására HUP0301479A2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10036645 2000-07-26
DE10123447A DE10123447A1 (de) 2000-07-26 2001-05-14 Cilansetron enthaltende Arzneimittel zur Behandlung nicht-obstipativer männlicher IBS-Patienten
PCT/EP2001/008260 WO2002007713A2 (de) 2000-07-26 2001-07-18 Cilansetron enthaltende arzneimittel zur behandlung nicht-obstipativer männlicher ibs-patienten

Publications (1)

Publication Number Publication Date
HUP0301479A2 true HUP0301479A2 (hu) 2003-09-29

Family

ID=26006529

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301479A HUP0301479A2 (hu) 2000-07-26 2001-07-18 Cilansetron alkalmazása nemobstipációs férfi IBS-betegek kezelésére szolgáló gyógyszerkészítmény elżállítására

Country Status (16)

Country Link
EP (1) EP1307195A2 (hu)
JP (1) JP2004504343A (hu)
CN (1) CN1444479A (hu)
AR (1) AR028970A1 (hu)
AU (1) AU2001276409A1 (hu)
BR (1) BR0112690A (hu)
CA (1) CA2417677A1 (hu)
CZ (1) CZ2003158A3 (hu)
HU (1) HUP0301479A2 (hu)
IL (1) IL153972A0 (hu)
MX (1) MXPA02012917A (hu)
NO (1) NO20030373L (hu)
PL (1) PL363517A1 (hu)
RU (1) RU2003104798A (hu)
SK (1) SK1272003A3 (hu)
WO (1) WO2002007713A2 (hu)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0216027D0 (en) 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
WO2005073220A1 (ja) * 2004-01-30 2005-08-11 Yamanouchi Pharmaceutical Co., Ltd. 下痢型過敏性腸症候群治療剤
BRPI0503488A (pt) * 2004-01-30 2006-03-07 Astellas Pharma Inc agente de tratamento para sìndrome de intestino irritável com diarréia predominante
JP4632204B2 (ja) * 2005-09-21 2011-02-16 アステラス製薬株式会社 下痢型過敏性腸症候群治療剤
US7662831B2 (en) 2006-07-27 2010-02-16 Wyeth Llc Tetracyclic indoles as potassium channel modulators
US7601856B2 (en) 2006-07-27 2009-10-13 Wyeth Benzofurans as potassium ion channel modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721139D0 (en) * 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments
GB9930077D0 (en) * 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments

Also Published As

Publication number Publication date
NO20030373D0 (no) 2003-01-24
WO2002007713A3 (de) 2002-11-14
EP1307195A2 (de) 2003-05-07
PL363517A1 (en) 2004-11-29
NO20030373L (no) 2003-01-24
BR0112690A (pt) 2003-06-24
AR028970A1 (es) 2003-05-28
JP2004504343A (ja) 2004-02-12
CZ2003158A3 (cs) 2003-08-13
SK1272003A3 (en) 2003-07-01
MXPA02012917A (es) 2003-05-14
WO2002007713A2 (de) 2002-01-31
IL153972A0 (en) 2003-07-31
CN1444479A (zh) 2003-09-24
RU2003104798A (ru) 2004-06-27
CA2417677A1 (en) 2003-01-27
AU2001276409A1 (en) 2002-02-05

Similar Documents

Publication Publication Date Title
CY1105082T1 (el) Χρηση της φλιβανσepινης στην αγωγη διαταραχων της σεξουαλικης επιθυμιας
ECSP034922A (es) Pirrolopirimidinas
CY1107838T1 (el) Παραγωγα αδαμαντανιου για τη θεραπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων
CY1109422T1 (el) Παραγωγα φαιναιθανολαμινης για θεραπεια ασθενειων του αναπνευστικου
NO20024005D0 (no) Pteridinforbindelser for behandling av psoriasis
NO20031019D0 (no) Vedvarende frigivelsesformuleringer av oksymorfon
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
HUP0202570A1 (hu) Izoflavonokat és analogonjait tartalmazó készítmények és terápiás alkalmazásuk
RS20050070A (en) Use of 1kb kinase inhibitors for the treatment of pain
CY1111396T1 (el) Ρινικη χορηγηση μετοκλοπραμιδης για την αγωγη της γαστροπαρεσης
MXPA04005886A (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitirptamina-6.
HUP0302874A2 (hu) Eljárás risperidon előállítására
MXPA03010549A (es) Formas de dosificacion de oxcarbazepina.
HUP0301991A2 (hu) IL-18-inhibitorok alkalmazása atheroszklerózis kezelésére és/vagy megelżzésére
IL153680A0 (en) Aplidine derivatives and methods for the preparation thereof
HUP0402281A2 (hu) Endotelin receptor antagonisták alkalmazása daganatos betegségek kezelésére alkalmas gyógyszerkészítmények előállítására
ATE438618T1 (de) Inhibitoren von humanem adam-10
PT1390371E (pt) Oxazolo- e furopirimidinas e sua utilizacao em medicamentos contra tumores
UA83821C2 (ru) Производные бензолсульфонамидов, способ их получения и их применение для лечения воспалительных заболеваний и утоления боли
HUP0100080A2 (hu) Mirtazapin alkalmazása alvásiapnoe kezelésére szolgáló gyógyszerkészítmény előállítására
HUP0301479A2 (hu) Cilansetron alkalmazása nemobstipációs férfi IBS-betegek kezelésére szolgáló gyógyszerkészítmény elżállítására
HUP0203906A2 (en) Aplidine treatment of cancers
MXPA04005809A (es) Inhibidores de proteinas quinasas.
HUP0000756A2 (hu) Levobupivakain vagy ropivakain alkalmazása migrén kezelésére alkalmas gyógyszerkészítmények előállítására
MXPA04001986A (es) Composiciones y metodos para el tratamiento de enfermedades relacionadas a la inmunidad.